journal
MENU ▼
Read by QxMD icon Read
search

Expert Opinion on Emerging Drugs

journal
https://www.readbyqxmd.com/read/30422005/emerging-cell-cycle-inhibitors-for-treating-metastatic-castration-resistant-prostate-cancer
#1
Anupam Batra, Eric Winquist
Introduction Disease progression despite androgen suppression defines lethal castration-resistant prostate cancer (CRPC). Most of these cancers remain androgen receptor (AR)-signalling dependent. Therapy for metastatic CRPC includes abiraterone acetate, enzalutamide, docetaxel, cabazitaxel, sipuleucel-T, and radium-223. However, survival remains modest for men with progressive disease despite AR-targeted therapy and docetaxel, and therefore novel treatments are needed. Areas covered Recent evidence of genomic heterogeneity and sensitivity to PARP inhibitors supports investigation of targeted agents in CRPC...
November 13, 2018: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/30415584/disease-modifying-drugs-in-osteoarthritis-current-understanding-and-future-therapeutics
#2
Win Min Oo, ShirleyPei-Chun Yu, Matthew Sean Daniel, David John Hunter
Osteoarthritis (OA) is a leading cause of pain and disability among adults with a current prevalence of around 15% and a predicted prevalence of 35% in 2030 for symptomatic OA. It is increasingly recognized as a heterogeneous multi-faceted joint disease with multi-tissue involvement of varying severity. Current therapeutic regimens for OA are only partially effective and often have significant associated toxicities. There are no disease-modifying drugs approved by the regulatory bodies. Areas covered: We reviewed the opportunities within key OA pathogenetic mechanism: cartilage catabolism/anabolism, pathological remodelling of subchondral bone and synovial inflammation to identify targeted disease-modifying osteoarthritis drugs (DMOADs), based on compounds currently in Phase II and III stages of clinical development in which x-ray and/or MRI was used as the structural outcome with/without symptomatic outcomes according to regulatory requirements...
November 12, 2018: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/30376740/an-update-emerging-drugs-to-treat-squamous-cell-carcinomas-of-the-head-and-neck
#3
Yoon Se Lee, Daniel E Johnson, Jennifer R Grandis
Subsequent to the 2006 FDA approval of cetuximab, a variety of molecular targeting agents have been evaluated in head and neck squamous cell carcinoma (HNSCC). The treatment outcomes of recurrent and/or metastatic (R/M) HNSCC, in particular, remain dismal. The 2016 FDA approval of PD-1 immune checkpoint inhibitors has expanded the treatment options for R/M HNSCC and highlights the potential for immune-based therapies. Areas covered: We will review the clinical application of EGFR-targeted agents, alone and in combination with other drugs...
October 30, 2018: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/30251907/emerging-drugs-for-focal-epilepsy
#4
Marco Mula
Epilepsy is one of the most serious neurological conditions, affecting almost 50 million people around the world. Despite more than 20 antiepileptic drugs (AEDs) available, seizures are still uncontrolled in one third of patients. Areas covered: The present paper reviews current compounds in preclinical and clinical development for the treatment of focal epilepsies and new potential molecular targets recently identified. Expert opinion: 1OP-2198, Cannabidavirin, Everolimus, FV-082, Ganaxolone, Minocycline, NAX 810-2, Padsevonil and Selurampanel seem to be particularly promising in focal epilepsy...
September 2018: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/30251897/expert-opinion-on-existing-and-developing-drugs-to-treat-female-sexual-dysfunction
#5
Melanie K Miller, Joshua R Smith, Jacqueline J Norman, Anita H Clayton
Female sexual dysfunction (FSD) is a highly prevalent, yet commonly underdiagnosed and undertreated condition. This paper reviews the diagnostic terminology for FSD, and basic sexual physiology in women. The Food and Drug Administration (FDA) approved drugs for FSD are discussed, followed by investigational drugs for FSD currently in phase 2 or 3 clinical trials, reasons for failure of drug development, and potential future drug targets. Areas covered: A literature review was conducted for available treatments for FSD: flibanserin, estrogen, ospemifene and prasterone...
September 2018: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/30251885/evolution-in-the-treatment-landscape-of-non-small-cell-lung-cancer-with-alk-gene-alterations-from-the-first-to-third-generation-of-alk-inhibitors
#6
Alessia Spagnuolo, Paolo Maione, Cesare Gridelli
The medical treatment of non-small cell lung cancer (NSCLC) has radically changed over the last 10 years thanks to new molecular-targeted drugs able to act on biological mechanisms involved in tumor development. One such mechanism is the aberrant anaplastic lymphoma kinase (ALK) activation: patients with ALK-driven NSCLC benefit from treatments that selectively inhibit its pathogenetic mechanism. Areas covered: The first-generation ALK inhibitor is crizotinib, initially used in Europe as second-line treatment for ALK-positive metastatic NSCLC patients, then approved as the standard first-line (already approved in the USA as front-line therapy)...
September 2018: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/30251552/emerging-parp-inhibitors-for-treating-breast-cancer
#7
Marie Robert, Anne Patsouris, Jean-Sébastien Frenel, Carole Gourmelon, Paule Augereau, Mario Campone
Some breast cancers harbor defects in DNA repair pathways, including BRCA1 and BRCA2 mutations, leading to a genomic instability. Compromised DNA-damage repair response is found in 11 to 42% of triple negative breast cancers, with a frequency varying according to family history and ethnicity. The oral PARP inhibitors are a promising strategy in breast cancer exploiting Homologous Deficient Recombination deficiency (HRD) by a synthetic lethal approach. Several PARP inhibitors have currently reached early phase trials with studies on going in the adjuvant, neoadjuvant and metastatic setting...
September 2018: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/30244605/expert-opinion-on-emerging-urate-lowering-therapies
#8
Lisa K Stamp, Tony R Merriman, Jasvinder A Singh
There has been a resurgence in gout therapeutics in the last decade, not only for the management of gout flares, but also for the treatment of hyperuricemia. This editorial summarizes new, emerging therapies for people with gout. Areas covered: We review several new therapies for gout, including those that are focused on lowering serum urate (levotofisopam, ulodesine, verinurad, merbarone, KUX-1151, UR-1102, FYU-981, SEL-212), or treating gout flares (canakinumab, bucillamine) or both (arhalofenate, diacerein)...
September 2018: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/30032674/emerging-antibacterial-and-antiviral-drugs-for-treating-respiratory-tract-infections
#9
Marco Mantero, Paola Rogliani, Mario Cazzola, Francesco Blasi, Marta Di Pasquale
Management of LRTI is becoming more frequently challenging since the emergence of multidrug resistance bacteria and the increase of severe viral infection, reducing the number of available effective drugs. The clinical evaluation of new therapeutic associations is mandatory to cope with the increases in resistance, in association with better infection control and antimicrobial policies. Areas covered: We searched Pubmed in English language of phase I, II, III clinical trials and approved treatments for LRTI, between 2006 and 2016...
September 2018: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/29848130/emerging-drugs-for-eosinophilic-esophagitis
#10
REVIEW
Robert D Pesek, Sandeep K Gupta
Eosinophilic esophagitis (EoE) is rare but incidence and prevalence is increasing. EoE is characterized by eosinophilic inflammation of the esophagus causing gastrointestinal symptoms such as abdominal pain, vomiting, reflux, dysphagia, and food impactions. If untreated, remodeling and fibrosis of the esophagus can occur and stricture formation may result. Current treatment options are limited to food-restriction diets or medications including proton pump inhibitors (PPIs) or swallowed corticosteroids. Significant progress has been made in understanding the underlying mechanisms of EoE allowing for development of drugs that target specific points in EoE pathways...
June 2018: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/29781323/targeting-the-b-cell-receptor-pathway-a-review-of-current-and-future-therapies-for-non-hodgkin-s-lymphoma
#11
REVIEW
Thomas D Rodgers, Patrick M Reagan
The B-cell receptor (BCR) pathway is a crucial aspect of mature lymphocytes and is maintained in B-cell neoplasms. Many small module inhibitors targeting kinases within the BCR pathway are approved, with others in development, offering alternative treatment options to standard chemoimmunotherapy. Areas covered: This review covers both approved inhibitors and investigational inhibitors of spleen tyrosine kinase (SYK), Bruton's tyrosine kinase (BTK), and phosphoinositide-3-kinase (PI3K) in the treatment of B-cell lymphomas...
June 2018: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/29737220/emerging-reverse-transcriptase-inhibitors-for-hiv-1-infection
#12
REVIEW
Mohammad A Rai, Sam Pannek, Carl J Fichtenbaum
There are 36.7 million people living with HIV with 20.9 million having access to antiretroviral therapy (ART). Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) remain the 'backbone' of ART. However, the currently available nine NRTIs and five non-nucleoside reverse transcriptase inhibitors (NNRTIs) have significant side effects and resistance profiles. Areas covered: We summarize the mechanisms of resistance and other limitations of the existing NRTIs/NNRTIs. GS-9131, MK-8591, Elsulfavirine and Doravirine are four new agents that are furthest along in development...
June 2018: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/29730950/emerging-intravesical-drugs-for-the-treatment-of-non-muscle-invasive-bladder-cancer
#13
REVIEW
Jasper Crijnen, Theo M De Reijke
Bladder cancer (BC) is a severe health burden: and has high recurrence and progression rates. Standard treatment starts with TURB followed by intravesical chemotherapy with Mitomycin C or immunotherapy with BCG. However, successful management still remains a challenge, because approximately 30% of patients have recurrence or progression within 5 years, and treatment has considerable side effects. Anticipating on the upcoming BCG shortage emphasizes, moreover, the necessity to develop and study novel treatments...
June 2018: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/29718783/an-update-on-emerging-drugs-for-the-treatment-of-idiopathic-pulmonary-fibrosis
#14
REVIEW
Shambhu Aryal, Steven D Nathan
Idiopathic pulmonary fibrosis is a chronic, progressive fibrotic lung disease of unknown etiology associated with a high morbidity and mortality. The hallmark of the disease is impaired healing after alveolar epithelial injury in the setting of a genetic predisposition. Development of two new drugs has changed the landscape of the treatment of IPF but more work is needed to improve outcomes and improve survival. Areas covered: The development of two antifibrotic agents, nintedanib and pirfenidone has been an exciting landmark in the treatment of IPF...
June 2018: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/29638150/emerging-drugs-for-primary-progressive-multiple-sclerosis
#15
REVIEW
Ram Narendra Narayan, Thomas Forsthuber, Olaf Stüve
The identification of effective therapies for progressive forms of multiple sclerosis (MS) has remains a priority and challenge for the global MS community. Despite a few proposed mechanisms, a more complete understanding of the mechanisms involved in the pathogenesis of these MS phenotypes, animal models that incorporate these pathogenic characteristics, novel trial designs, drug repurposing strategies, and new models of collaboration between clinical and basic science personnel may be required in identifying effective therapies...
June 2018: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/29595348/parp-inhibitors-for-homologous-recombination-deficient-prostate-cancer
#16
REVIEW
Eric S Christenson, Emmanuel S Antonarakis
Prostate adenocarcinoma represents a leading cause of cancer-related mortality. Increased emphasis on understanding the molecular basis of prostate cancer has identified a substantial burden of homologous recombination (HR) pathway mutations, which are enriched in castrate-resistant disease. This discovery has yielded novel therapeutic opportunities. Areas covered: We will discuss the treatment of castrate-resistant prostate cancer (CRPC), with a focus on the use of poly (ADP-ribose) polymerase (PARP) inhibitors in this space...
June 2018: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/29528256/emerging-growth-factor-receptor-antagonists-for-ovarian-cancer-treatment
#17
REVIEW
Luisa Bonilla, Amit Oza, Stephanie Lheureux
Epithelial Ovarian Cancer (EOC) is the most lethal gynecological malignancy. EOC outcomes remain unsatisfactory despite aggressive surgical approach, disease chemo-sensitivity and recent introduction of agents targeting angiogenesis and tumour genome instability. Advances in EOC research have allowed for a tailored treatment approach and accelerated development of novel treatments strategies from bench to bed side, anticipated to improve patient outcomes. Areas covered: Comprehensive review of growth factor receptor antagonists for EOC treatment currently in different stages of development was performed...
March 2018: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/29508636/emerging-pharmacotherapies-for-the-treatment-of-atrial-fibrillation
#18
REVIEW
Alessandro Capucci, Laura Cipolletta, Federico Guerra, Irene Giannini
The main aim of current research on the field of atrial fibrillation (AF) treatment is to find new antiarrhythmic drugs with less side effects. Areas covered: Dronedarone and vernakalant showed promising result in term of efficacy and safety in selected patients. Ranolazine and colchicine are obtaining a role as a potential antiarrhythmic drug. Ivabradine is used in experimental studies for the rate control of AF. Moreover, new compounds (vanoxerine, moxonidine, budiodarone) are still under investigation. Monoclonal antibodies or selective antagonist of potassium channel are under investigation for long term maintenance of sinus rhythm...
March 2018: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/29486606/emerging-treatment-options-for-uterine-fibroids
#19
REVIEW
Jacques Donnez, Pablo Arriagada, Olivier Donnez, Marie-Madeleine Dolmans
Uterine fibroids (also known as leiomyomas or myomas) are the most common form of benign uterine tumors. Current management strategies involve mainly surgical interventions, but the choice of treatment is guided by patient age and desire to preserve fertility or avoid 'radical' surgery such as hysterectomy. Areas covered: There is growing evidence of the crucial role of progesterone pathways in the pathophysiology of uterine fibroids, leading to increasing use of selective progesterone receptor modulators (SPRMs) such as ulipristal acetate...
March 2018: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/29480036/emerging-drugs-for-the-treatment-of-myelofibrosis
#20
REVIEW
Aditya Shreenivas, John Mascarenhas
Myelofibrosis (MF) is a Philadelphia chromosome-negative myeloproliferative neoplasm (MPN). It can be sub-categorized into primary myelofibrosis, post polycythemia vera myelofibrosis and post essential thrombocythemia myelofibrosis. MF is a life-threatening hematologic malignancy characterized by dysregulation of the Janus associated kinase (JAK)/signal transducer and activator of transcription (STAT) signaling network and a heightened inflammatory state. Areas covered: We cover the pathogenesis, clinical features, new prognostic models, current treatment of MF and discuss agents in development...
March 2018: Expert Opinion on Emerging Drugs
journal
journal
40009
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"